ClinicalTrials.gg
CompletedNCT04550962REVEALUpdated Jul 20, 2026

Description of Characteristics, Such as Age, Previous and Concurrent Treatments, Associated Diseases, of Patients With Asthma Treated With Dupilumab (DUPIXENT)

An observational study in Asthma, sponsored by Sanofi. Completed at 41 sites in 12 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-07-20.

Sponsored by Sanofi · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
376
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 37 studies in Asthma by Sanofi — 3 open to participants now, 5 under way, 1 of them phase 3. Asthma · Sanofi.

Started
2020
with 2 others
Observational
5 of 37
1 open now
Registered
23rd of 37
by date

Among the 37 studies in Asthma by Sanofi, this one is one of 3 that started in 2020, is one of 5 observational ones, and was the 23rd registered.

Asthma

4,849 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

3 of the 37 studies in Asthma by Sanofi are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 416 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Asthma by Sanofi, or all of them as a file.
02

Study summary

Primary Objective:

The primary objective of the study is to characterize patients initiating DUPIXENT for asthma in a real-world setting, with respect to their medical history, including asthma history and asthma treatment history, socio-demographic, biomarkers (including Fractional exhaled nitric oxide [FeNO]), and concomitant treatments for asthma.

Secondary Objectives:

The secondary objectives of the study are:

  • To characterize real-world use patterns of DUPIXENT for asthma (eg, most commonly used regimens, reason for initiation of new asthma treatments, concomitant therapies, treatment durations, and reasons for discontinuation and/or switching)
  • To assess the effectiveness of DUPIXENT in asthma patients in a real world setting (lung function improvement, exacerbation rate, asthma control)
  • To assess comorbid type 2 conditions (atopic/allergic) and patterns of use and effects of treatment in comorbid conditions in asthma patients treated with Dupixent
  • To collect data on HealthCare Resource Utilization (HCRU)
  • To collect safety data on study participants in the real-world setting.
Read the detailed description

Each patient will be followed for up to 36 months.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with asthma initiating DUPIXENT for their asthma according to the prescribing information in effect in each country.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, 12 years or older
  • Initiating treatment with Dupixent for asthma according to the country-specific prescribing information
  • Willing and able to comply with the required clinic visits, study procedures and assessments.
  • Provided signed

Exclusion criteria

Exclusion Criteria:

  • Patients who have a to Dupixent according to the country-specific prescribing information
  • Treatment with Dupixent within 6 months before the baseline visit. Note: for patients who have been treated previously with DUPIXENT a of 6 months is required before Visit 1.
  • Any condition that, in the opinion of the Investigator, may interfere with patient's ability to participate in the study, such as short , substance abuse, severe cognitive impairment, or other comorbidities that can predictably prevent the patient from adequately completing the schedule of visits and assessments
  • Patients currently participating in any interventional clinical trial which modifies patient care.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
376 participants (actual)
Patient registry
No
Biospecimen retention
None retained

Groups and cohorts

  • Participants with asthma

    Eligible participants are initiating treatment with Dupixent for asthma according to the prescribing information in effect in each country

    Drug: Dupilumab SAR231893

Interventions

  • Pharmaceutical form:solution Route of administration: subcutaneous Dose regimen:

    Also known as: Dupixent

06

What researchers measure

Primary outcomes

  1. Baseline Characteristics: Socio-demographics

    Socio-demographics including but not limited to gender, age, race, weight, and height

    Time frame: At baseline

  2. Baseline Characteristics: Medical history

    Including asthma history and asthma treatment history

    Time frame: At baseline

  3. Baseline Characteristics: Disease characteristics

    Disease characteristics including asthma, comorbid conditions, family history and history of inflammatory diseases

    Time frame: At baseline

  4. Baseline Characteristics: Biomarkers

    Including fractional exhaled nitric oxide (FeNo), blood eosinophils count, immunoglobulin E (IgE total/specific)

    Time frame: At baseline

  5. Baseline Characteristics: Concomitant treatments for asthma

    Time frame: At baseline

Secondary outcomes

  1. Dupixent and other asthma treatment use patterns

    Including doses and dose frequency, treatment duration, asthma treatment associations (eg, Dupixent monotherapy, Dupixent + inhaled corticosteroids (ICS), Dupixent + ICS + additional controllers, oral corticosteroid (OCS) burst), and reasons for initiation and for discontinuation/switching.

    Time frame: Baseline to Month 36

  2. Lung function

    Pre and post bronchodilator (BD) forced expiratory volume in 1 second (FEV1) over time.

    Time frame: Baseline to Month 36

  3. Annualized exacerbation rate

    A severe exacerbation event is defined as a deterioration of asthma requiring: * Use of systemic corticosteroids for ≥3 days; or * Hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids.

    Time frame: Baseline to Month 36

  4. Patient reported outcomes: Asthma Control Questionnaire (6-item) (ACQ-6)

    To evaluate asthma control

    Time frame: Baseline to Month 36

  5. Patient reported outcomes: Patient Oriented Eczema Measure (POEM) among participants with atopic dermatitis

    Among participants with atopic dermatitis

    Time frame: Baseline to Month 36

  6. Patient reported outcomes: Allergic Rhinitis Visual Analogue Scale (AR-VAS) among participants with allergic rhinitis

    Among participants with allergic rhinitis

    Time frame: Baseline to Month 36

  7. Patient reported outcomes: Sino-nasal Outcome Test (SNOT-22)

    Among participants with chronic rhinosinusitis with nasal polyps \[CRSwNP\] and chronic rhinosinusitis \[CRS\] without nasal polyps \[NP\])

    Time frame: Baseline to Month 36

  8. Healthcare Resource Utilization

    The Healthcare Resource Utilization (HCRU) collects information on unscheduled healthcare resource encounters including inpatient visits, emergency room visits, physician office visits related to asthma, including the dates of visits and duration of any hospitalizations, together with the reason for the visits

    Time frame: Baseline to Month 36

  9. Number of participants with adverse events (AE) and serious adverse events (SAE)

    Time frame: Baseline to Month 36

07

Study locations

41 sites
  • Investigational Site Number : 0320005
    La Plata, Buenos Aires B1900BNN, Argentina
  • Investigational Site Number : 0320006
    Villa Rosa, Buenos Aires 1631, Argentina
  • Investigational Site Number : 0320001
    Ciudad Autonoma Bs As, C1121ABE, Argentina
  • Investigational Site Number : 0320008
    Ciudad Autonoma Buenos Aires, C1425BEN, Argentina
  • Investigational Site Number : 0320009
    San Miguel de Tucumán, T4000IAI, Argentina
  • Investigational Site Number : 0320004
    Santa Fe, 3000, Argentina
  • Investigational Site Number : 1520001
    Santiago, Reg Metropolitana de Santiago 7500692, Chile
  • Investigational Site Number : 1520002
    Quillota, Valparaiso 2260877, Chile
  • Investigational Site Number : 1700009
    Barranquilla, 080001, Colombia
  • Investigational Site Number : 1700004
    Bogotá, Colombia
  • Investigational Site Number : 1700003
    Bucaramanga, Colombia
  • Investigational Site Number : 3760008
    Ashdod, 7747629, Israel
  • Investigational Site Number : 3760004
    Ashkelon, 78278, Israel
  • Investigational Site Number : 3760005
    Jerusalem, 91031, Israel
  • Investigational Site Number : 3760003
    Jerusalem, 91120, Israel
  • Investigational Site Number : 3760001
    Kfar Saba, 4428164, Israel
  • Investigational Site Number : 3760006
    Rehovot, 7642001, Israel
  • Investigational Site Number : 3760007
    Tel Aviv, 64239, Israel
  • Investigational Site Number : 4140001
    Kuwait City, 00000, Kuwait
  • Investigational Site Number : 4220002
    Beirut, 11 0236, Lebanon
  • Investigational Site Number : 4220001
    Beirut, Lebanon
  • Investigational Site Number : 4220003
    El Achrafiyé, Lebanon
  • Investigational Site Number : 4840003
    Durango, 34000, Mexico
  • Investigational Site Number : 6340001
    Doha, Qatar
  • Investigational Site Number : 6430005
    Chelyabinsk, 454091, Russia
  • Investigational Site Number : 6430007
    Moscow, 105077, Russia
  • Investigational Site Number : 6430004
    Moscow, 115522, Russia
  • Investigational Site Number : 6430006
    Rostov-on-Don, 344012, Russia
  • Investigational Site Number : 6430008
    Saratov, 410012, Russia
  • Investigational Site Number : 6430002
    Stavropol, 355020, Russia
  • Investigational Site Number : 6820005
    Jeddah, 23433, Saudi Arabia
  • Investigational Site Number : 6820004
    Mecca, 24246, Saudi Arabia
  • Investigational Site Number : 6820002
    Riyadh, 11525, Saudi Arabia
  • Investigational Site Number : 6820001
    Riyadh, 12713, Saudi Arabia
  • Investigational Site Number : 7020002
    Singapore, 119074, Singapore
  • Investigational Site Number : 7020001
    Singapore, 169308, Singapore
  • Investigational Site Number : 7840006
    Abu Dhabi, 0000, United Arab Emirates
  • Investigational Site Number : 7840007
    Dubai, 2, United Arab Emirates
  • Investigational Site Number : 7840001
    Dubai, 4545, United Arab Emirates
  • Investigational Site Number : 7840004
    Sharjah city, 00000, United Arab Emirates
  • Investigational Site Number : 7840002
    Sharjah city, 3499, United Arab Emirates
08

References and documents

Publications

  • Maspero JF, Arnaout RK, Vargas-Ramirez L, Mobayed H, Mahboub B, Irani C, Bar-Shai A, Koh MS, Chao J, Zaghloul S, Kwah JH, Dewhurst J, Al-Ahmad MS. Baseline Characteristics of Patients with Asthma Initiating Dupilumab in a Real-World Setting: The REVEAL Registry. Adv Ther. 2026 Jun 10. doi: 10.1007/s12325-026-03623-2. Online ahead of print. PubMed 42268495 ↗

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Jun 2026, 67 months.

Of 90 industry-sponsored observational studies under Asthma, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 58. This study's 67 months is above that.

Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2020
First posted
Sep 16, 2020
StartActual
Nov 2, 2020
Primary completionActual
Jun 18, 2026
CompletionActual
Jun 18, 2026
Last update
Jul 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04550962
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Sep 16, 2020
Start date
Nov 2, 2020
Primary completion
Jun 18, 2026
Completion
Jun 18, 2026
Last update
Jul 20, 2026

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion